AbbVie is a Dividend King with a strong product lineup. Bristol Myers Squibb offers a high dividend yield and has underrated ...

Bristol-Myers Squibb and BioNTech announced a major deal worth up to $11 billion in early June. Click here to find out why I ...

We recently published a list of Was Jim Cramer Right About These 9 Stocks? In this article, we are going to take a look at ...

Wall Street's major averages took home gains on Friday, with the S&P 500 reclaiming the 6,000 level for the first time since late February, as sentiment was boosted by a strong May jobs report.

Bristol Myers Squibb has agreed to pay up to $11.1 billion to partner with Germany's BioNTech and develop the latter's ...

Princeton: BioNTech SE and Bristol Myers Squibb have announced that the companies have entered into an agreement for the ...

Bristol Myers Squibb will pay $1.5 billion upfront to BioNTech SE for rights to co-develop and commercialize the German ...

Despite its success in advanced melanoma, Bristol Myers Squibb’s fixed-dose PD-1/LAG-3 combo, Opdualag, failed to move the ...

Bristol Myers Squibb and BioNTech to co-develop cancer immunotherapy BNT327 in a deal worth up to $11.1 billion.

BMY strikes a billion-dollar deal with BNTX to co-develop BNT327, a bispecific antibody targeting PD-L1 and VEGF-A in solid ...

The oncology giant will pay $1.5 billion to co-develop a BioNTech drug that targets the proteins PD-L1 and VEGF, following ...

Bristol-Myers Squibb's financial position improved, it raised both its EPS guidance and revenue expectations, and Opdivo's ...